The role of PD-1/PD-L1 inhibitors in the treatment for non-small cell lung cancer (NSCLC)

Che Li; Manyi Xu

doi:10.54097/hset.v8i.1108

Authors

Che Li
Manyi Xu

DOI:

https://doi.org/10.54097/hset.v8i.1108

Keywords:

PD-1/PD-L1 Inhibitor, Non-small Cell Lung Cancer (NSCLC), Nivolumab, Pembrolizumab, Atezolizumab, Durvalumab.

Abstract

Non-small cell lung cancer (NSCLC) is a frequent cancer that affects people around the world. Checkpoint inhibitors are the most intensively studied treatment methods at present. Activation of PD-1/PD-L1 is accountable for suppressing the activation, proliferation, and cytotoxic secretion of T cells. By giving PD-1 /PD-L1 inhibitors, an individual's immune system can be boosted to some extent. Nivolumab, pembrolizumab, atezolizumab, and durvalumab have shown to be effective for NSCLC patients in clinical trials. The effectiveness of PD-1/PD-L1 inhibitors combining with SBRT, chemotherapy, or other checkpoint inhibitors to treat NSCLC has also been demonstrated. However, PD-1/PD-L1 inhibitors also have drawbacks, such as non-specific recognition misses, and immune-related adverse events. This article mainly discusses the role of PD-1/PD-L1 inhibitors in the treatment for NSCLC.

Downloads

Download data is not yet available.

References

R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2019,” CA. Cancer J. Clin., vol. 69, no. 1, pp. 7–34, 2019, doi: 10.3322/caac.21551.

C. Gridelli et al., “Non-small-cell lung cancer,” Nat. Rev. Dis. Prim., vol. 1, pp. 1–16, 2015, doi: 10.1038/nrdp.2015.9.

D. R. Robinson et al., “Integrative clinical genomics of metastatic cancer,” Nature, vol. 548, no. 7667, pp. 297–303, 2017, doi: 10.1038/nature23306.

I. Mellman, G. Coukos, and G. Dranoff, “Cancer immunotherapy comes of age,” Nature, vol. 480, no. 7378, pp. 480–489, 2011, doi: 10.1038/nature10673.

Y. Han, D. Liu, and L. Li, “PD-1/PD-L1 pathway: current researches in cancer.,” Am. J. Cancer Res., vol. 10, no. 3, pp. 727–742, 2020, [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/32266087.

L. Guo, H. Zhang, and B. Chen, “Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor,” J. Cancer, vol. 8, no. 3, pp. 410–416, 2017, doi: 10.7150/jca.17144.

N. Patsoukis, Q. Wang, L. Strauss, and V. A. Boussiotis, “Revisiting the PD-1 pathway,” Sci. Adv., vol. 6, no. 38, Sep. 2020, doi: 10.1126/sciadv.abd2712.

Jain, Prantesh et al. “Role of immune-checkpoint inhibitors in lung cancer.” Therapeutic advances in respiratory disease vol. 12 (2018): 1753465817750075. doi:10.1177/1753465817750075

Guo, Liting et al. “Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor.” Journal of Cancer vol. 8,3 410-416. 10 Feb. 2017, doi:10.7150/jca.17144

X. Shen and B. Zhao, “Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: Meta-analysis,” BMJ, vol. 362, pp. 1–9, 2018, doi: 10.1136/bmj.k3529.

Chen, Yu et al. “SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.” Journal of hematology & oncology vol. 13,1 105. 28 Jul. 2020, doi:10.1186/s13045-020-00940-z

Timmerman, Robert et al. “Stereotactic body radiation therapy for inoperable early stage lung cancer.” JAMA vol. 303,11 (2010): 1070-6. doi:10.1001/jama.2010.261

Reits, Eric A et al. “Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.” The Journal of experimental medicine vol. 203,5 (2006): 1259-71. doi:10.1084/jem.20052494

Weichselbaum, Ralph R et al. “Radiotherapy and immunotherapy: a beneficial liaison?.” Nature reviews. Clinical oncology vol. 14,6 (2017): 365-379. doi:10.1038/nrclinonc.2016.211

Frey, Benjamin et al. “Immunomodulation by ionizing radiation-impact for design of radio-immunotherapies and for treatment of inflammatory diseases.” Immunological reviews vol. 280,1 (2017): 231-248. doi:10.1111/imr.12572

Deng, Liufu et al. “Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.” The Journal of clinical investigation vol. 124,2 (2014): 687-95. doi:10.1172/JCI67313

Luke, Jason J et al. “Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 36,16 (2018): 1611-1618. doi:10.1200/JCO.2017.76.2229

Theelen, Willemijn S M E et al. “Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial.” JAMA oncology vol. 5,9 (2019): 1276-1282. doi:10.1001/jamaoncol.2019.1478

Wu, Junjie, and David J Waxman. “Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy.” Cancer letters vol. 419 (2018): 210-221. doi:10.1016/j.canlet.2018.01.050

S. L. Topalian et al., “Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer,” N. Engl. J. Med., vol. 366, no. 26, pp. 2443–2454, Jun. 2012, doi: 10.1056/NEJMoa1200690.

M. Sznol et al., “Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).,” J. Clin. Oncol., vol. 31, no. 18_suppl, pp. CRA9006–CRA9006, Jun. 2013, doi: 10.1200/jco.2013.31.18_suppl.cra9006.

M. C. Andrews et al., “Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade,” Nat. Med., vol. 27, no. 8, pp. 1432–1441, 2021, doi: 10.1038/s41591-021-01406-6.

M. J. Friedrich, “Immunotherapy 2.0: Improving the Response to Checkpoint Inhibitors,” JAMA - J. Am. Med. Assoc., vol. 321, no. 2, pp. 131–133, 2019, doi: 10.1001/jama.2018.18306.

A. L. Shergold, R. Millar, and R. J. B. Nibbs, “Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade,” Pharmacol. Res., vol. 145, p. 104258, 2019, doi: 10.1016/j.phrs.2019.104258.

M. M. Gubin et al., “Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens,” Nature, vol. 515, no. 7528, pp. 577–581, 2014, doi: 10.1038/nature13988.

L. C. Platanias, “Mechanisms of type-I- and type-II-interferon-mediated signalling,” Nat. Rev. Immunol., vol. 5, no. 5, pp. 375–386, 2005, doi: 10.1038/nri1604.

E. A. Akbay et al., “Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors,” Cancer Discov., vol. 3, no. 12, pp. 1355–1363, 2013, doi: 10.1158/2159-8290.CD-13-0310.